ACP2

Summary

ACP2 (acid phosphatase 2, lysosomal, HGNC:123) is a protein-coding gene on chromosome 11p11.2, encoding Lysosomal acid phosphatase (P11117).

The protein encoded by this gene belongs to the histidine acid phosphatase family, which hydrolyze orthophosphoric monoesters to alcohol and phosphate. This protein is localized to the lysosomal membrane, and is chemically and genetically distinct from the red cell acid phosphatase. Mice lacking this gene showed multiple defects, including bone structure alterations, lysosomal storage defects, and an increased tendency towards seizures. An enzymatically-inactive allele of this gene in mice showed severe growth retardation, hair-follicle abnormalities, and an ataxia-like phenotype. Alternatively spliced transcript variants have been found for this gene. A C-terminally extended isoform is also predicted to be produced by the use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism.

Source: NCBI Gene 53 — RefSeq curated summary.

At a glance

• Gene–disease (curated): lysosomal acid phosphatase deficiency (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 83 total — 2 pathogenic
• MANE Select transcript: NM_001610

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:123
Approved symbol	ACP2
Name	acid phosphatase 2, lysosomal
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	LAP
Ensembl gene	ENSG00000134575
Ensembl biotype	protein_coding
OMIM	171650
Entrez	53

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 16 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000256997, ENST00000527256, ENST00000529444, ENST00000533929, ENST00000671941, ENST00000672073, ENST00000672075, ENST00000672166, ENST00000672351, ENST00000672636, ENST00000672728, ENST00000672787, ENST00000673184, ENST00000673511, ENST00000673562, ENST00000673604, ENST00000897033, ENST00000897034, ENST00000897035, ENST00000897036, ENST00000897037, ENST00000897038, ENST00000919384, ENST00000941444

RefSeq mRNA: 6 — MANE Select: NM_001610 NM_001302489, NM_001302490, NM_001302491, NM_001302492, NM_001357016, NM_001610

CCDS: CCDS76402, CCDS76403, CCDS76404, CCDS7928, CCDS91470

Canonical transcript exons

ENST00000672073 — 11 exons

Exon	Start	End
ENSE00003478978	47245305	47245394
ENSE00003493017	47245682	47245834
ENSE00003493827	47242723	47242898
ENSE00003498171	47243018	47243124
ENSE00003537582	47243239	47243321
ENSE00003557803	47248038	47248133
ENSE00003570317	47244735	47244867
ENSE00003651530	47247641	47247727
ENSE00003669745	47245474	47245572
ENSE00003892063	47239302	47240249
ENSE00003896112	47248676	47248814

Expression profiles

Bgee: expression breadth ubiquitous, 275 present calls, max score 95.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.3365 / max 424.9363, expressed in 1819 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119561	40.3970	1819
119562	0.7530	293
119559	0.1411	79
119560	0.0454	28

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	95.20	gold quality
body of pancreas	UBERON:0001150	93.73	gold quality
right adrenal gland	UBERON:0001233	93.12	gold quality
left adrenal gland	UBERON:0001234	93.00	gold quality
liver	UBERON:0002107	92.95	gold quality
right adrenal gland cortex	UBERON:0035827	92.87	gold quality
stromal cell of endometrium	CL:0002255	92.64	gold quality
jejunal mucosa	UBERON:0000399	92.63	gold quality
left adrenal gland cortex	UBERON:0035825	92.63	gold quality
adrenal gland	UBERON:0002369	92.27	gold quality
adrenal cortex	UBERON:0001235	92.07	gold quality
adrenal tissue	UBERON:0018303	92.06	gold quality
mucosa of transverse colon	UBERON:0004991	92.03	gold quality
pancreas	UBERON:0001264	90.97	gold quality
saliva-secreting gland	UBERON:0001044	90.81	gold quality
duodenum	UBERON:0002114	90.64	gold quality
body of stomach	UBERON:0001161	90.57	gold quality
spleen	UBERON:0002106	90.56	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	90.45	gold quality
minor salivary gland	UBERON:0001830	90.29	gold quality
metanephros cortex	UBERON:0010533	90.20	gold quality
transverse colon	UBERON:0001157	90.18	gold quality
prefrontal cortex	UBERON:0000451	90.07	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.01	gold quality
parotid gland	UBERON:0001831	89.96	gold quality
small intestine	UBERON:0002108	89.87	gold quality
right lobe of thyroid gland	UBERON:0001119	89.83	gold quality
adult mammalian kidney	UBERON:0000082	89.71	gold quality
nasal cavity epithelium	UBERON:0005384	89.51	gold quality
lymph node	UBERON:0000029	89.47	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

44 targeting ACP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-8077	99.17	66.67	862

Literature-anchored findings (GeneRIF, showing 5)

• An enzymatically inactive allele of mouse Acp2 causes cerebellum abnormalities, growth retardation, hair-follicle abnormalities, and an ataxia-like phenotype. (PMID:15503243)
• Data show that lysosomal acid phosphatase 2 (ACP2) was overexpressed in colorectal cancer (CRC) and associated with poor outcome in stage II CRC, and that high expression of ACP2 patients were more sensitive to chemotherapy than those with a low expression, suggesting ACP2 as a marker for CRC patients receiving chemotherapy. (PMID:28076332)
• In addition to replicating a previously identified genome-wide significant locus for corneal astigmatism near the PDGFRA gene, gene-based analysis identified three novel candidate genes, CLDN7, ACP2, and TNFAIP8L3, that warrant further investigation to understand their role in the pathogenesis of corneal astigmatism. (Meta-analysis) (PMID:29422769)
• Clinical and molecular evaluation of 13 Brazilian patients with Gomez-Lopez-Hernandez syndrome. (PMID:33381921)
• LAP-deficient mice exhibit multiple defects including bone structure alterations, lysosomal storage defects in the kidneys and central nervous system, and an increased tendency towards seizures. (PMID:9228031)

Cross-species orthologs

19 orthologs

Organism	Symbol	Gene ID
danio_rerio	acp2	ENSDARG00000007244
mus_musculus	Acp2	ENSMUSG00000002103
rattus_norvegicus	Acp2	ENSRNOG00000013594
drosophila_melanogaster	Acph-1	FBGN0000032
drosophila_melanogaster	CG9449	FBGN0036875
drosophila_melanogaster	CG9451	FBGN0036876
drosophila_melanogaster	CG9452	FBGN0036877
caenorhabditis_elegans		WBGENE00007328
caenorhabditis_elegans		WBGENE00007331
caenorhabditis_elegans		WBGENE00008801
caenorhabditis_elegans		WBGENE00008802
caenorhabditis_elegans		WBGENE00008804
caenorhabditis_elegans		WBGENE00009146
caenorhabditis_elegans		WBGENE00011879
caenorhabditis_elegans		WBGENE00015161
caenorhabditis_elegans		WBGENE00016152
caenorhabditis_elegans		WBGENE00022181
caenorhabditis_elegans		WBGENE00022770
caenorhabditis_elegans		WBGENE00206373

Paralogs (5): ACP3 (ENSG00000014257), ACP4 (ENSG00000142513), FRA10AC1 (ENSG00000148690), PXYLP1 (ENSG00000155893), ACP6 (ENSG00000162836)

Protein

Protein identifiers

Lysosomal acid phosphatase — P11117 (reviewed: P11117)

All UniProt accessions (9): A0A5F9ZH40, A0A5F9ZH82, A0A5F9ZHR7, A0A5F9ZI20, B7Z6U3, B7Z7D2, P11117, E9PHY0, E9PQY3

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Lysosome membrane. Lysosome lumen.

Post-translational modifications. The membrane-bound form is converted to the soluble form by sequential proteolytic processing. First, the C-terminal cytoplasmic tail is removed. Cleavage by a lysosomal protease releases the soluble form in the lysosome lumen. N-glycosylated. The intermediates formed during enzymatic deglycosylation suggest that all eight predicted N-glycosylation sites are used.

Disease relevance. Lysosomal acid phosphatase has been shown to be deficient in cultured fibroblasts from patients manifesting intermittent vomiting, hypotonia, lethargy, opisthotonos, terminal bleeding and death in early infancy.

Similarity. Belongs to the histidine acid phosphatase family.

Isoforms (2)

UniProt ID	Names	Canonical?
P11117-1	1	yes
P11117-2	2

RefSeq proteins (6): NP_001289418, NP_001289419, NP_001289420, NP_001289421, NP_001343945, NP_001601* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000560	His_Pase_clade-2	Family
IPR029033	His_PPase_superfam	Homologous_superfamily
IPR033379	Acid_Pase_AS	Active_site
IPR050645	Histidine_acid_phosphatase	Family

Pfam: PF00328

Catalyzed reactions (Rhea), 1 shown:

• a phosphate monoester + H2O = an alcohol + phosphate (RHEA:15017)

UniProt features (23 total): glycosylation site 8, disulfide bond 3, sequence variant 3, splice variant 2, topological domain 2, active site 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P11117-F1	92.09	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 42 (nucleophile); 287 (proton donor)

Disulfide bonds (3): 159–370, 212–310, 345–349

Glycosylation sites (8): 177, 191, 267, 322, 331, 92, 133, 167

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 187 (showing top): MULLIGHAN_NPM1_SIGNATURE_3_UP, GOBP_VACUOLE_ORGANIZATION, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOCC_VACUOLAR_MEMBRANE, ROVERSI_GLIOMA_COPY_NUMBER_UP, KEGG_LYSOSOME, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, MODULE_256, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, NRF2_01, GOBP_LYTIC_VACUOLE_ORGANIZATION, JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_DN, MODULE_333, CETS1P54_01

GO Biological Process (2): skeletal system development (GO:0001501), lysosome organization (GO:0007040)

GO Molecular Function (3): acid phosphatase activity (GO:0003993), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (5): lysosome (GO:0005764), lysosomal membrane (GO:0005765), membrane (GO:0016020), lysosomal lumen (GO:0043202), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lysosome	2
system development	1
lytic vacuole organization	1
phosphatase activity	1
binding	1
catalytic activity	1
lytic vacuole	1
lytic vacuole membrane	1
cellular anatomical structure	1
vacuolar lumen	1
extracellular vesicle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

117 interactions, top by confidence:

A	B	Type	Score
FBXO6	MAN2B1	psi-mi:“MI:0914”(association)	0.640
TRHR	ACP2	psi-mi:“MI:0915”(physical association)	0.560
ATN1	ACP2	psi-mi:“MI:0915”(physical association)	0.560
PAK1	ACP2	psi-mi:“MI:0915”(physical association)	0.560
KLK6	ACP2	psi-mi:“MI:0915”(physical association)	0.560
GAB2	ACP2	psi-mi:“MI:0915”(physical association)	0.560
SLC7A1	TMEM223	psi-mi:“MI:0914”(association)	0.530
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
IPPK	TMEM223	psi-mi:“MI:0914”(association)	0.530
ST8SIA3	KLRG2	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
ADGRG5	KLRG2	psi-mi:“MI:0914”(association)	0.530
S1PR2	PALM3	psi-mi:“MI:0914”(association)	0.530
BTNL3	FAM171A2	psi-mi:“MI:0914”(association)	0.530
SPPL2B	UQCRQ	psi-mi:“MI:0914”(association)	0.530
SPRING1	PLSCR1	psi-mi:“MI:0914”(association)	0.530
ATP6V0A2	B4GALT3	psi-mi:“MI:0914”(association)	0.530
CBX1	KPNA3	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
TMEM192	STXBP3	psi-mi:“MI:0914”(association)	0.530

BioGRID (114): ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS), ACP2 (Affinity Capture-MS)

ESM2 similar proteins: A0A2D0TC04, A6H730, A6H757, B1H1P9, B6EWW8, D2GZV9, E1BPW0, E1C1L6, F8S0Z7, J3SBP3, J3SEZ3, O14638, O35409, O75356, P06802, P07686, P0DQQ4, P11117, P15309, P15396, P20060, P20611, P20646, P22413, P24638, P24822, P49614, P58242, P70627, P97675, Q0P5F0, Q29548, Q3KQG9, Q3MI05, Q3U4B4, Q4R5N9, Q5NVF6, Q5R5M5, Q5R8C0, Q5VXJ0

Diamond homologs: A6H730, B1H1P9, D3YTS9, P11117, P15309, P20611, P20646, P24638, Q0P5F0, Q10944, Q19076, Q3KQG9, Q4R5N9, Q5BLY5, Q5NVF6, Q5R8C0, Q8CE08, Q9BZG2, Q09451, A6H757, Q09448, Q09549, Q8BP40, Q9NPH0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 138 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Lysosphingolipid and LPA receptors	6	51.9×	5e-07
Class A/1 (Rhodopsin-like receptors)	9	7.6×	8e-04
GPCR ligand binding	9	6.6×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	7	12.7×	1e-03
phospholipase C-activating G protein-coupled receptor signaling pathway	8	8.7×	1e-03
G protein-coupled receptor signaling pathway	13	3.9×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	59
Likely benign	5
Benign	6

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
151005	GRCh38/hg38 11p11.2(chr11:47210659-47427331)x1	Pathogenic
4076016	GRCh37/hg19 11p11.2(chr11:47219637-47454749)x1	Pathogenic

SpliceAI

1684 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47240256:A:AC	acceptor_gain	1.0000
11:47240256:A:C	acceptor_gain	1.0000
11:47242894:AATTC:A	acceptor_gain	1.0000
11:47242896:TTC:T	acceptor_gain	1.0000
11:47242899:C:CC	acceptor_gain	1.0000
11:47242899:CTGAG:C	acceptor_loss	1.0000
11:47242900:T:C	acceptor_loss	1.0000
11:47242907:C:CT	acceptor_gain	1.0000
11:47242908:G:T	acceptor_gain	1.0000
11:47242910:C:CT	acceptor_gain	1.0000
11:47243013:CTCA:C	donor_loss	1.0000
11:47243014:TCA:T	donor_loss	1.0000
11:47243015:CA:C	donor_loss	1.0000
11:47243016:A:AC	donor_gain	1.0000
11:47243016:AC:A	donor_gain	1.0000
11:47243016:ACCC:A	donor_loss	1.0000
11:47243017:C:CC	donor_gain	1.0000
11:47243017:CC:C	donor_gain	1.0000
11:47243027:T:TA	donor_gain	1.0000
11:47243120:TCGTG:T	acceptor_gain	1.0000
11:47243121:CGTG:C	acceptor_gain	1.0000
11:47243121:CGTGC:C	acceptor_gain	1.0000
11:47243122:GTG:G	acceptor_gain	1.0000
11:47243122:GTGC:G	acceptor_loss	1.0000
11:47243123:TG:T	acceptor_gain	1.0000
11:47243123:TGCT:T	acceptor_loss	1.0000
11:47243124:GCTG:G	acceptor_loss	1.0000
11:47243125:C:A	acceptor_loss	1.0000
11:47243125:C:CC	acceptor_gain	1.0000
11:47243126:T:A	acceptor_loss	1.0000

AlphaMissense

2744 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:47243120:T:A	D287V	0.999
11:47243121:C:G	D287H	0.998
11:47245793:A:C	S113R	0.998
11:47245793:A:T	S113R	0.998
11:47245795:T:G	S113R	0.998
11:47245820:G:C	S104R	0.998
11:47245820:G:T	S104R	0.998
11:47245822:T:G	S104R	0.998
11:47243120:T:G	D287A	0.997
11:47248065:C:A	W61C	0.997
11:47248065:C:G	W61C	0.997
11:47243120:T:C	D287G	0.996
11:47245308:A:C	C212W	0.996
11:47245309:C:T	C212Y	0.996
11:47245548:A:G	C159R	0.996
11:47245792:C:G	A114P	0.996
11:47247724:C:A	G72W	0.996
11:47248067:A:G	W61R	0.996
11:47248067:A:T	W61R	0.996
11:47248114:C:G	R45P	0.996
11:47248120:C:A	G43V	0.996
11:47248122:A:C	H42Q	0.996
11:47248122:A:T	H42Q	0.996
11:47243121:C:A	D287Y	0.995
11:47243122:G:C	H286Q	0.995
11:47243122:G:T	H286Q	0.995
11:47243124:G:C	H286D	0.995
11:47245779:A:G	L118P	0.995
11:47248045:A:G	L68S	0.995
11:47248115:G:T	R45S	0.995

dbSNP variants (sampled 300 via entrez): RS1000214685 (11:47250638 A>C), RS1000376431 (11:47244326 C>A,T), RS1000998483 (11:47244101 T>C), RS1001114591 (11:47243708 G>GCCCT), RS1001182545 (11:47249389 T>A,C), RS1001286007 (11:47250589 CCTT>C), RS1002324150 (11:47239258 C>A,G), RS1002598624 (11:47245996 G>T), RS1003051911 (11:47241378 A>G), RS1003191238 (11:47247420 G>A), RS1003194632 (11:47246173 G>A,C), RS1003252203 (11:47241210 G>A), RS1003799278 (11:47246854 C>T), RS1003929660 (11:47243918 C>T), RS1004006501 (11:47243648 C>G,T)

Disease associations

OMIM: gene MIM:171650 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
lysosomal acid phosphatase deficiency	Limited	Autosomal recessive

Mondo (1): lysosomal acid phosphatase deficiency (MONDO:0008705)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004521_165	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST005232_56	Neuroticism	1.000000e-16
GCST006611_78	HDL cholesterol	8.000000e-45
GCST006940_77	Neurociticism	2.000000e-10
GCST006943_9	Feeling miserable	5.000000e-09
GCST006949_2	Suffering from nerves	4.000000e-16
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST010002_238	Refractive error	2.000000e-14
GCST90020026_776	Hip index	1.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0009598	feeling miserable measurement
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C562645	Acid Phosphatase Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11039149	ACP2, NR1H3	3	2.75	1	atenolol;verapamil

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, increases expression	3
Tobacco Smoke Pollution	affects expression	2
Cyclosporine	decreases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
ferrous chloride	decreases expression	1
pyrene	affects expression, affects cotreatment	1
phenanthrene	affects cotreatment, affects expression	1
naphthalene	affects expression, affects cotreatment	1
anthracene	affects expression, affects cotreatment	1
2,3-dimethoxy-1,4-naphthoquinone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
14-deoxy-11,12-didehydroandrographolide	decreases expression	1
abrine	increases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Antimony	decreases expression	1
Antimony Potassium Tartrate	decreases expression	1
Cadmium	decreases reaction, increases abundance, increases palmitoylation	1
Carbamazepine	affects expression	1
Chromium	decreases expression	1
Dimethylnitrosamine	decreases expression	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.